Warfarin administration, which is a vitamin K antagonist, has been the primary precept for AF ablation anticoagulation as it is associated with lower risk of bleeding and stroke, while a new oral anticoagulant called Dabigatran, which is a non-vitamin K antagonist, has showed safety and efficacy outcomes similar or superior to those of warfarin regarding periprocedual stroke prevention (2). Furthermore, an evidence favor dabigatran over warfarin as it has an advantage of not requiring regular monitoring. However, the major concern of performing catheter ablation with Dabigatran is the risk of bleeding, particularly life-threatening bleeding (1,
Warfarin administration, which is a vitamin K antagonist, has been the primary precept for AF ablation anticoagulation as it is associated with lower risk of bleeding and stroke, while a new oral anticoagulant called Dabigatran, which is a non-vitamin K antagonist, has showed safety and efficacy outcomes similar or superior to those of warfarin regarding periprocedual stroke prevention (2). Furthermore, an evidence favor dabigatran over warfarin as it has an advantage of not requiring regular monitoring. However, the major concern of performing catheter ablation with Dabigatran is the risk of bleeding, particularly life-threatening bleeding (1,